The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Phase I study of OBP-301 for locally advanced esophageal cancer
Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, outlines the rationale of an ongoing NRG Oncology NRG-GI007 Phase I study of telomelysin and chemoradiation (CRT) for patients with locally advanced esophageal and gastroesophageal adenocarcinoma who are not candidates for surgery. Telomelysin is a conditionally-restricted, replication-competent adenovirus that adds a hTERT gene promoter, replicating only in tumor cells to cause lysis. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
Disclosures
Dr Ku reports Apexigen (consulting), AstraZeneca (research support), BMS (research support, consulting), Daiichi-Sankyo (research support), Merck (research support, consulting), Oncolys (research support), Pieris (research support, consulting), Zymeworks (research support).
